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This is a retrospective chart review of a 3 years' experience of amphotericin B lipid complex (ABLC, Abelcet) utilization for the management of suspected invasive fungal disease at a single center in Lebanon between January 2011 and January 2014. It included 79 adult neutropenic cancer patients who received at least two doses of ABLC (5 mg/kg/day). The hospital's Institutional Review Board approved this study, and no patient consent was needed due to its observational nature. We recorded baseline clinical characteristics; strategy of initiating ABLC based on an empiric or pre-emptive approach; previous antifungal therapy; adverse drug events including drug-delivery reactions, nephrotoxicity, hypokalemia and hepatotoxicity. We evaluated response to therapy through measuring clinical success or failure and mortality among these patients. ABLC was used in this study based on guideline recommendations and on several comparative studies evaluating safety, efficacy and cost-effectiveness of ABLC compared with other formulations of amphotericin B. 1, 3, 4 During the study period, primary antifungal prophylaxis was prescribed at the beginning of neutropenia according to the 2011 National Comprehensive Cancer Network clinical practice guidelines of neutropenic fever. 5 High-risk patients including those with leukemia undergoing induction/ salvage chemotherapy and allogeneic HSCT recipients received prophylactic voriconazole. 5 Intermediate-risk patients including autologous HSCT recipients with mucositis only received prophylactic fluconazole or micafungin. 5 Patients with chronic lymphocytic leukemia were prescribed fluconazole in cases of prolonged neutropenia for 47 days or old age. 5 Patients with lymphoma or multiple myeloma were not put on an antifungal prophylaxis regimen except fluconazole when there was evidence of oral and/or esophageal candida infections. 5 Low-risk patients including those who receive standard chemotherapy regimens for most solid tumors and patients with anticipated neutropenia for o7 days were not given any prophylactic antifungals. 5 Empiric and pre-emptive antifungal therapies were defined according to the 2010 Infectious Diseases Society of America clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer. 6 Febrile yet clinically stable patients, at 72-96 h after the onset of fever having no focus of infection and negative serum galactomannan, were treated with caspofungin. ABLC was initiated in instances of persistent neutropenic fever of unknown etiology for ⩾ 4 days in a patient receiving appropriate antibacterial therapy in the following cases:
(1) presence of infiltrates or nodules on chest computed tomography (CT) scans /X-ray ± positive serum galactomannan in patients who were previously on mold-active azole prophylaxis (voriconazole), (2) clinical instability in high-risk patients with previous mold-active prophylaxis (voriconazole) and (3) febrile autologous HSCT recipients with mucositis who are already on micafungin prophylaxis with negative serum galactomannan.
Clinical success was defined as resolution of all pretreatment signs and symptoms of suspected invasive fungal disease (including radiologic changes on chest X-ray/CT scans) by the end of therapy. 3, 7 Clinical failure was defined as the progression of disease or the lack of significant improvement or worsening of the same parameters including death the of the patient or drug withdrawal with evidence of ongoing infection after 7 days of antifungal therapy or onset of toxicity that would require discontinuation of the drug. 3, 7 Nephrotoxicity was defined as a doubling in serum creatinine anytime above baseline during ABLC therapy. 7 Hypokalemia was defined as decrease in K + level to o 3.5 meq/L. Moderate hypokalemia was having K + level (42.5-3.54 meq/L) and severe hypokalemia o 2.5 meq/L. 7 Reversable/correctable hypokalemia was defined as K + level increasing to 43.5 meq/L during ABCL treatment through intravenous and oral potassium salt supplementation. 7 Hepatotoxicity was defined as a threefold increase in hepatic transaminases anytime above baseline during ABLC therapy. 7 Data were statistically analyzed using SPSS version 19 (Chicago, IL, USA). Descriptive statistics and frequencies were performed to obtain mean and percentages, respectively.
Details of patients' clinical characteristics and treatment outcome are summerized in Table 1 . Thirty percent of the patients (24/79) were treated with ABLC empirically and 70% (55/79) pre-emptively. In the empiric category, 22/24 patients achieved clinical success while 2/24 patients only failed therapy, thus resulting in 92% success rate. In the pre-emptive category, 35/55 patients achieved clinical success yet 20/55 patients failed therapy thus resulting in 64% success rate. The overall success rate was 72.2% (57/79 patients). Total mortality and 30-day post-treatment mortality were mostly present in the pre-emptive category (21/79 and 6/79 patients, respectively). The calculated mortality is crude all-cause mortality not restricted to fungal infection as etiology. Adverse drug events associated with ABLC therapy are listed in Table 2 . Nephrotoxicity occurred in 19/79 patients (24.1%). Nine (11.4%) patients out of 79 had baseline serum creatinine above 1 mg/dL. Three (33.3%) patients out of them doubled serum creatinine and remained persistently elevated throughout ABLC treatment. No hypokalemia was observed in 23/79 (29.1%) patients during ABLC treatment. Hypokalemia occurred in 56/79 (70.9%) patients. Moderate hypokalemia was observed in 48/79 patients (60.8%) and severe hypokalemia in 8/79 (10.1%) patients. In the severe hypokalemia group, 7/8 (87.5%) patients had correctable serum potassium levels while one had ABLC discontinued. Nine (11.39%) patients out of 79 showed a threefold increase in hepatic transaminases levels above baseline throughout ABLC therapy. All patients were premedicated before ABLC therapy yet infusion reactions including fever, chills and rigors were observed in 25/79 (31.6%). Premedication drugs used included intravenous rapid acting corticosteroids ± intravenous paracetamol ± antihistamines.
To our knowledge, this is the only study in the Middle East region encompassing 79 hematology/oncology and HSCT adult patients from a single center. Our overall response rate was better than that of a subset of patients with presumed fungal infection treated with ABLC in a study by Mehta et al. 8 (72 vs 63%). The latter was retrospective including 64 adult patients with hematological malignancies who were immunocompromised after HSCT or chemotherapy, and were treated with ABLC (5 mg/kg/day), with a total of 68 courses of ABLC therapy (16/68 courses for confirmed cases and 52/68 courses for presumed fungal infections). 8 Our study population is comparable to the subset of presumed fungal infections in the Mehta et al. 8 study. In another key clinical trial on 556 patients conducted by Walsh et al., 3 the response rate was much less than ours (57%). The main difference between our patient population and Walsh's is that ABLC was used in our study to treat fungal infections in immunocompromised patients in indications outside the Food and Drug Admninstration approval but mentioned in several regional and international guidelines. Yet, Walsh used it strictly in patients intolerant or refractory to conventional amphotericin B, as per Food and Drug Admninstration approval.
The safety and tolerability profile represents a major issue that affects the choice of antifungal therapy. Our results Letter to the Editor show nephrotoxicity in 24% of patients receiving ABLC yet improvement in serum creatinine was seen in 5.3% knowing that all patients in this study had conditions predisposing them to renal impairment, including intake of nephrotoxic anti-infectives and cytotoxic chemotherapeutic agents. Nephrotoxicity is the most clinically significant adverse drug event of amphotericin B, not to mention that the concomitant use of other nephrotoxic drugs increases the risk of this nephrotoxicity. 4 In a study by Alexander and Wingard on renal safety in ABLC-treated patients, nephrotoxicity was observed in only 13% of subjects despite the high risk of renal impairment carried by these patients. 9 Walsh et al. 3 found that ABLC therapy was associated with a significant improvement in renal function, particularly among patients with pre-existing renal dysfunction or nephrotoxicity induced by conventional amphotericin B. In a review and meta-analysis that compared the drug-induced nephrotoxicity associated with either ABLC or liposomal amphotericin B (L-AmB), Safdar et al. 10 reported an increased probability of nephrotoxicity in patients who were treated with ABLC as compared with L-AmB (Odd's ratio, 1.75; relative risk, 1.55). This was due to the significant lack of homogeneity across these studies, where the results were heavily influenced by an unexplained high rate of nephrotoxicity in one particular study by Wingard et al. 11 When that study was removed from the analysis, the risk of nephrotoxicity was more similar between the two preparations (Odd's ratio, 1.12; relative risk, 1.09). 10 Hypokalemia secondary to urinary potassium wasting is a frequent adverse drug event of amphotericin B therapy where serum potassium levels should be routinely monitored. 4 In our study, moderate hypokalemia was observed in around 61% of the cases and severe hypokalemia in 10%. Serum potassium levels were correctable in 87.5% of patients in both groups by supplying intravenous and oral potassium salts as per hospital guidelines. According to a study by Clark et al., 12 electrolyte abnormalities were present in 18/36 (50%) patients on ABLC who experienced hypokalemia ( o3 mmol/L). Drug-delivery reactions such as fever and chills, which occur with ABLC, are generally mild to moderate and usually last for only 2-3 days after the onset of therapy. 13 They are not dose related and generally diminish with subsequent infusions. 13 In our study, the overall rate of drug-delivery reactions was 31.6% despite of premedication along with a slow infusion rate that was not standardized during the whole study period. Premedication schemes are based on the administration of systemic corticosteroids ± paracetamol ± antihistamines. In a study by O'Connor and Borley, 14 100 mg of hydrocortisone was used as premedication 15-30 min before ABLC infusion. This resulted in a lower incidence of drug-delivery reactions than had been reported in published literature for ABLC, 15.3% for the initial infusion and 2.3% for subsequent infusions.
14 This study has a major limitation in that it is only descriptive and retrospective. No comparison was made with other antifungals or a control group, in addition to the heterogeneity of our patient population including different categories of risk to fungal infections as mentioned previously. Although the immunologic response in this heterogeneous group of patients differs from one clinical condition to another, it is still comparable to earlier studies that evaluated the efficacy and tolerability of polyene antifungals. 3, 8 Fungal attributable mortality was not discussed because of the complexity of the cases even if it may be patially attributed to fungal infection.
In conclusion, our results showed a higher efficacy of ABLC to what has been previously mentioned in litterature with a comparable toxicity profile. Our data was based on empiric or pre-emptive therapy due to difficulty in taking tissue biopsies in such immunocompromised category of patients. We recommend putting efforts into this issue and ultimately in developing an institutional antifungal stewardship program, which will preserve our antifungal armamentarium.
